Welcome to our dedicated page for XOMA Royalty Corporation news (Ticker: XOMA), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty Corporation stock.
About XOMA Royalty Corporation
XOMA Royalty Corporation (NASDAQ: XOMA) is a biotechnology royalty aggregator that plays a pivotal role in advancing the development of innovative therapeutic solutions. The company specializes in acquiring the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. By doing so, XOMA provides non-dilutive, non-recourse funding to biotech firms, enabling them to accelerate the development of their internal drug pipelines or meet other corporate objectives.
Business Model and Operations
XOMA's business model is centered around acquiring royalty and milestone rights from therapeutic assets across all stages of development. These assets span a wide range of therapeutic areas, including oncology, rare diseases, women's health, and cardio-respiratory conditions. By focusing on royalty aggregation rather than direct drug development, XOMA minimizes operational risks while maximizing potential financial returns. The company’s portfolio includes rights to commercial products such as VABYSMO®, OJEMDA™, MIPLYFFA™, and DSUVIA®, as well as a pipeline of investigational compounds with significant market potential.
Industry Significance
Operating at the intersection of biotechnology and finance, XOMA serves as a critical enabler for biotech innovation. Its royalty aggregation model provides biotech companies with the financial flexibility to advance groundbreaking therapies without the burden of equity dilution or traditional debt. This unique approach not only supports the development of life-saving treatments but also allows XOMA to build a diversified portfolio of assets that generate sustainable cash flows over time.
Portfolio and Market Position
XOMA boasts an extensive and growing portfolio of over 70 assets, including both commercial and investigational therapies. The company's portfolio strategy emphasizes diversification across therapeutic areas and stages of development, thereby mitigating risks associated with the inherently unpredictable nature of drug development. Recent acquisitions, such as economic interests in seralutinib for pulmonary arterial hypertension and XACIATO™ for bacterial vaginosis, highlight XOMA's commitment to expanding its asset base while addressing unmet medical needs.
Competitive Differentiation
XOMA differentiates itself through its expertise in asset valuation, strategic capital deployment, and risk diversification. Unlike traditional biotech firms that focus on drug development, XOMA’s royalty aggregation model allows it to benefit from the success of multiple therapeutic candidates without bearing the direct costs and risks of R&D. This positions XOMA as a trusted financial partner for biotech companies and a unique investment opportunity within the biotech sector.
Challenges and Risk Management
While XOMA's business model reduces operational risks, it is not without challenges. The company’s revenue streams depend on the successful development, regulatory approval, and market adoption of its partnered assets. To mitigate these risks, XOMA employs a disciplined approach to asset selection, focusing on therapies with strong clinical and commercial potential. Its diversified portfolio further helps to balance the inherent uncertainties of the biotech industry.
Conclusion
In summary, XOMA Royalty Corporation represents a unique and innovative approach to supporting biotech innovation. By acquiring royalty and milestone rights, the company enables the development of life-saving therapies while building a diversified and sustainable revenue model. With its extensive portfolio, strategic focus, and financial expertise, XOMA continues to play a crucial role in advancing human health and shaping the future of biotechnology.
XOMA Corporation (Nasdaq: XOMA) announced key financial updates for Q3 2022, reporting total revenues of $0.5 million, down from $0.9 million in Q3 2021. The decline was mainly due to a lack of milestone revenue compared to the previous year. XOMA received its first royalty payment of $0.5 million from Roche related to VABYSMO® sales and also secured $2.5 million from Kuros following Regeneron’s acquisition of Checkmate Pharmaceuticals. The company ended Q3 with $78.3 million cash and no debt, despite a net loss of $4.2 million.
XOMA Corporation (Nasdaq: XOMA) announced cash dividends for its Series A and Series B Cumulative Preferred Stock. Holders of the 8.625% Series A stock will receive $0.53906 per share, while those with the 8.375% Series B stock will receive $0.52344 per depositary share. These dividends are payable on approximately October 17, 2022, to shareholders on record by October 3, 2022. XOMA operates as a biotechnology royalty aggregator, having acquired rights to over 70 assets linked to therapeutic candidates, providing funding to biotechs for their R&D initiatives.
XOMA Corporation will have its CEO, Jim Neal, present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 10:00 AM ET. The conference aims to highlight XOMA's role as a biotechnology royalty aggregator, helping companies enhance human health by acquiring future economic rights linked to pre-commercial therapeutic candidates. A live stream of the presentation will be accessible here and on XOMA's website. A replay will be available for 90 days post-event.
XOMA Corporation reported its second quarter 2022 financial results, achieving total revenues of $1.0 million, up from $0.9 million in Q2 2021. The net loss widened to $4.7 million compared to $2.2 million in the prior year. Cash at the end of June stood at $83.2 million, with no debt, which management believes will sustain operations for several years. The acquisition of Checkmate Pharmaceuticals resulted in a $2.5 million payment to XOMA, while Rezolute and Day One plan to advance to Phase 3 clinical trials, signaling positive progress in their pipelines.
XOMA Corporation (Nasdaq: XOMA) has announced cash dividends for holders of its Series A and B Cumulative Preferred Stock. Shareholders of the 8.625% Series A stock will receive $0.53906 per share, while holders of the 8.375% Series B stock will receive $0.52344 per depositary share. The dividends are scheduled for payment on July 15, 2022, to shareholders on record by July 1, 2022. XOMA plays a significant role as a biotechnology royalty aggregator, managing over 70 assets related to therapeutic candidates, providing crucial funding for biotech advancement.
XOMA Corporation, a biotechnology royalty aggregator, announced that its Chairman and CEO, Jim Neal, will present at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 10:00 AM ET. The presentation will be accessible online and archived for 90 days post-event. XOMA focuses on acquiring potential future earnings from pre-commercial therapeutic candidates, providing non-dilutive funding to sellers. The company's portfolio includes over 70 assets associated with drug products in development, underscoring its impact on improving human health.
XOMA Corporation (Nasdaq: XOMA) reported a strong financial performance for Q1 2022, with total revenues of $3.1 million, up from $0.4 million in Q1 2021. This increase was propelled by a $2 million milestone from Rezolute for the RZ358 study. The company concluded Q1 2022 with cash and restricted cash totaling $88.6 million and no debt. Notably, XOMA recognized a net loss of $2.3 million, a significant improvement compared to a $7.4 million loss in the prior year. The firm remains optimistic about its financial stability and future operations.
XOMA Corporation (Nasdaq: XOMA) announced cash dividends for holders of its Series A and Series B Cumulative Preferred Stock. Holders of the 8.625% Series A Cumulative Preferred Stock (Nasdaq: XOMAP) will receive $0.53906 per share, while holders of depositary shares representing 1/1000 of the Series B Cumulative Preferred Stock (Nasdaq: XOMAO) will receive $0.52344 per share. The dividends will be paid on or about April 15, 2022, to shareholders on record as of April 1, 2022.
On March 10, 2022, XOMA Corporation (Nasdaq: XOMA) announced that Chairman and CEO Jim Neal will present at Oppenheimer’s 32nd Annual Healthcare Conference on March 17, 2022, at 12:40 PM ET. This virtual event can be accessed through a direct link or via the investor relations section of XOMA's website, where a replay will be available for 90 days. XOMA specializes in acquiring future royalties from pre-commercial therapeutic candidates, providing non-dilutive funding to biotech companies. The company has an extensive portfolio with over 70 assets.
XOMA Corporation (Nasdaq: XOMA) reported a strong financial performance in 2021, earning $36.2 million in milestone payments and achieving positive operating cash flow for the second consecutive year. Key highlights include a $35 million milestone from its Anti-TGFβ Antibody License Agreement with Novartis. Total revenues reached $38.2 million in 2021, up from $29.4 million in 2020. The company ended the year with $95.4 million in cash and no debt. Significant advances include commercialization approval for a bispecific antibody and progress in multiple drug candidates. CEO succession planning is underway.
FAQ
What is the current stock price of XOMA Royalty Corporation (XOMA)?
What is the market cap of XOMA Royalty Corporation (XOMA)?
What does XOMA Royalty Corporation do?
How does XOMA generate revenue?
What is XOMA's business model?
What therapeutic areas does XOMA focus on?
What makes XOMA unique in the biotech industry?
What are some commercial assets in XOMA's portfolio?
How does XOMA mitigate risks in its business model?
Who benefits from XOMA's royalty aggregation model?
What role does XOMA play in the biotech industry?
What is XOMA's approach to portfolio management?
